The European Medicines Agency Review of Pazopanib for the Treatment of Advanced Renal Cell Carcinoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use-Reference-Cited by-同舟云学术

The European Medicines Agency Review of Pazopanib for the Treatment of Advanced Renal Cell Carcinoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

Published:2011-10-05 Issue:21 Volume:17 Page:6608-6614
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Nieto Maria,Borregaard Jeanett,Ersbøll Jens,ten Bosch George J.A.,van Zwieten-Boot Barbara,Abadie Eric,Schellens Jan H.M.,Pignatti Francesco

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A new framework for novel analogues of pazopanib as potent and selective human carbonic anhydrase inhibitors: Design, repurposing rational, synthesis, crystallographic, in vivo and in vitro biological assessments;European Journal of Medicinal Chemistry;2024-08

2. Therapeutic Drug Monitoring of Pazopanib in Renal Cell Carcinoma and Soft Tissue Sarcoma: A Systematic Review;Therapeutic Drug Monitoring;2024-04-30

3. Copper pyrazole complexes as potential anticancer agents: Evaluation of cytotoxic response against cancer cells and their mechanistic action at the molecular level;Coordination Chemistry Reviews;2024-01

4. Gene expression profile analysis to discover molecular signatures for early diagnosis and therapies of triple-negative breast cancer;Frontiers in Molecular Biosciences;2022-12-07

5. Design, synthesis, in vitro antiproliferative evaluation and GSK-3β kinase inhibition of a new series of pyrimidin-4-one based amide conjugates;Bioorganic Chemistry;2022-02